Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Buyru, Ayse Nur; Simsek, Eda Tanrikulu; Ekizoglu, Seda; Gulturk, Emine; Ferhanoglu, Burhan; Tuzuner, Nukhet; Demiroz, Ahu Senem; Aydin, Seniz Ongoren; Aydin, Yildiz; Soysal, Teoman; Ozbek, Ugur; Baslar, Zafer; Salihoglu, Ayse; Elverdi, Tugrul; Ar, Muhlis Cem; Eskazan, Ahmet Emre; Cengiz, Mahir

Tarih

2016

Yazar

Buyru, Ayse Nur

Simsek, Eda Tanrikulu

Ekizoglu, Seda

Gulturk, Emine

Ferhanoglu, Burhan

Tuzuner, Nukhet

Demiroz, Ahu Senem

Aydin, Seniz Ongoren

Aydin, Yildiz

Soysal, Teoman

Ozbek, Ugur

Baslar, Zafer

Salihoglu, Ayse

Elverdi, Tugrul

Ar, Muhlis Cem

Eskazan, Ahmet Emre

Cengiz, Mahir

Üst veri

Tüm öğe kaydını göster

Özet

Aims Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.

Bağlantı

http://hdl.handle.net/20.500.12627/91282
https://doi.org/10.1136/jclinpath-2015-203320

Koleksiyonlar

Makale [92796]